PerkinElmer (PKI) Declares $0.07 Quarterly Dividend; 0.2% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
- Qualcomm shares fall on Intel warning and legal concerns
- Marvell Technology shares drop on Lumentum deal concerns
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Oracle shares drop on AI spending concerns and Microsoft criticism
- SpaceX stock drops on launch setback and sector selloff
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
PerkinElmer (PKI) PT Raised to $175 at Stifel Following EPS and BioLegend Deal
July 27, 2021 6:18 AM EDTStifel analyst Daniel Arias raised the price target on PerkinElmer (NYSE: PKI) to $175.00 (from $155.00) while maintaining a Buy rating.
The analyst commented, "Yesterday, PKI announced another acquisition (the company's 7th announced since Horizon in Nov '20 - though by far the... More
PerkinElmer (PKI) Acquires BioLegend for $5.25B
July 26, 2021 6:30 AM EDTPerkinElmer (NYSE: PKI) announced it has entered into an agreement to acquire BioLegend, a leading, global provider of life science antibodies and reagents, for approximately $5.25 billion in a combination of cash and stock, subject to certain adjustments.
BioLegend provides its academic and biopharmaceutical customers with best-in-class antibodies and reagents in high-growth areas such as cytometry, proteogenomics, multiplex assays, recombinant proteins, magnetic cell separation and bioprocessing. The transaction will be the largest in PerkinElmers history and is expected to close by the end of the 2021 calendar year, subject to regulatory approvals and other customary... More



